Blood and marrow transplantation compensation

Perspective in payer and provider relations

James L. Gajewski, Mary Foote, John Tietjen, Ben Melson, Angela Simmons, Richard E. Champlin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The high cost per patient of hematopoietic cell transplantation (HCT) causes this therapy to be the focus of much controversy, given the competing societal demands to provide all possible therapy to preserve life while simultaneously limiting global health care expenditures. Treatment and eligibility decisions for HCT often are heavily scrutinized by both governmental and private payers and not simply determined by physicians, facility providers, and the patient. In an effort to control costs, payers have administrative infrastructure to review resource utilization by these patients. Additionally payers have developed payment methodologies, usually in the form of a case rate payment structure, that place facilities and physician providers of HCT at financial risk for adverse patient financial outcomes in an effort to promote optimal utilization and selection of patients for HCT. As providers enter into such financial risk arrangements with payers, the providers need to understand the true cost of care and be able to identify predictable and unpredictable outlier risks for the financial consequences of medical complications. HCT providers try to protect themselves from excessive financial risk by having different payment rates for different types of transplant, eg, autologous versus HLA or genotypically matched related versus HLA mismatched transplants. Because at certain times in the HCT process risk is more unpredictable, HCT providers require different payment system strategies for the different time periods of care such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well as short- and long-term follow-up. Involvement by clinicians is essential for this process to be done well, especially given the rapid changes technological innovation brings to HCT. Constant dialogue and interaction between providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this potentially lifesaving therapy.

Original languageEnglish (US)
Pages (from-to)427-432
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Cell Transplantation
Compensation and Redress
Transplantation
Bone Marrow
Utilization Review
Inventions
Physicians
Transplants
Costs and Cost Analysis
Cost Control
Autografts
Therapeutics
Disease Management
Health Expenditures
Patient Selection
Delivery of Health Care

Keywords

  • BMT
  • Center for Medicare and Medicaid Services
  • Compensation
  • Managed care

ASJC Scopus subject areas

  • Transplantation

Cite this

Blood and marrow transplantation compensation : Perspective in payer and provider relations. / Gajewski, James L.; Foote, Mary; Tietjen, John; Melson, Ben; Simmons, Angela; Champlin, Richard E.

In: Biology of Blood and Marrow Transplantation, Vol. 10, No. 7, 07.2004, p. 427-432.

Research output: Contribution to journalArticle

Gajewski, James L. ; Foote, Mary ; Tietjen, John ; Melson, Ben ; Simmons, Angela ; Champlin, Richard E. / Blood and marrow transplantation compensation : Perspective in payer and provider relations. In: Biology of Blood and Marrow Transplantation. 2004 ; Vol. 10, No. 7. pp. 427-432.
@article{12712edfdb0c4033a35ce55515913484,
title = "Blood and marrow transplantation compensation: Perspective in payer and provider relations",
abstract = "The high cost per patient of hematopoietic cell transplantation (HCT) causes this therapy to be the focus of much controversy, given the competing societal demands to provide all possible therapy to preserve life while simultaneously limiting global health care expenditures. Treatment and eligibility decisions for HCT often are heavily scrutinized by both governmental and private payers and not simply determined by physicians, facility providers, and the patient. In an effort to control costs, payers have administrative infrastructure to review resource utilization by these patients. Additionally payers have developed payment methodologies, usually in the form of a case rate payment structure, that place facilities and physician providers of HCT at financial risk for adverse patient financial outcomes in an effort to promote optimal utilization and selection of patients for HCT. As providers enter into such financial risk arrangements with payers, the providers need to understand the true cost of care and be able to identify predictable and unpredictable outlier risks for the financial consequences of medical complications. HCT providers try to protect themselves from excessive financial risk by having different payment rates for different types of transplant, eg, autologous versus HLA or genotypically matched related versus HLA mismatched transplants. Because at certain times in the HCT process risk is more unpredictable, HCT providers require different payment system strategies for the different time periods of care such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well as short- and long-term follow-up. Involvement by clinicians is essential for this process to be done well, especially given the rapid changes technological innovation brings to HCT. Constant dialogue and interaction between providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this potentially lifesaving therapy.",
keywords = "BMT, Center for Medicare and Medicaid Services, Compensation, Managed care",
author = "Gajewski, {James L.} and Mary Foote and John Tietjen and Ben Melson and Angela Simmons and Champlin, {Richard E.}",
year = "2004",
month = "7",
doi = "10.1016/j.bbmt.2004.03.004",
language = "English (US)",
volume = "10",
pages = "427--432",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Blood and marrow transplantation compensation

T2 - Perspective in payer and provider relations

AU - Gajewski, James L.

AU - Foote, Mary

AU - Tietjen, John

AU - Melson, Ben

AU - Simmons, Angela

AU - Champlin, Richard E.

PY - 2004/7

Y1 - 2004/7

N2 - The high cost per patient of hematopoietic cell transplantation (HCT) causes this therapy to be the focus of much controversy, given the competing societal demands to provide all possible therapy to preserve life while simultaneously limiting global health care expenditures. Treatment and eligibility decisions for HCT often are heavily scrutinized by both governmental and private payers and not simply determined by physicians, facility providers, and the patient. In an effort to control costs, payers have administrative infrastructure to review resource utilization by these patients. Additionally payers have developed payment methodologies, usually in the form of a case rate payment structure, that place facilities and physician providers of HCT at financial risk for adverse patient financial outcomes in an effort to promote optimal utilization and selection of patients for HCT. As providers enter into such financial risk arrangements with payers, the providers need to understand the true cost of care and be able to identify predictable and unpredictable outlier risks for the financial consequences of medical complications. HCT providers try to protect themselves from excessive financial risk by having different payment rates for different types of transplant, eg, autologous versus HLA or genotypically matched related versus HLA mismatched transplants. Because at certain times in the HCT process risk is more unpredictable, HCT providers require different payment system strategies for the different time periods of care such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well as short- and long-term follow-up. Involvement by clinicians is essential for this process to be done well, especially given the rapid changes technological innovation brings to HCT. Constant dialogue and interaction between providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this potentially lifesaving therapy.

AB - The high cost per patient of hematopoietic cell transplantation (HCT) causes this therapy to be the focus of much controversy, given the competing societal demands to provide all possible therapy to preserve life while simultaneously limiting global health care expenditures. Treatment and eligibility decisions for HCT often are heavily scrutinized by both governmental and private payers and not simply determined by physicians, facility providers, and the patient. In an effort to control costs, payers have administrative infrastructure to review resource utilization by these patients. Additionally payers have developed payment methodologies, usually in the form of a case rate payment structure, that place facilities and physician providers of HCT at financial risk for adverse patient financial outcomes in an effort to promote optimal utilization and selection of patients for HCT. As providers enter into such financial risk arrangements with payers, the providers need to understand the true cost of care and be able to identify predictable and unpredictable outlier risks for the financial consequences of medical complications. HCT providers try to protect themselves from excessive financial risk by having different payment rates for different types of transplant, eg, autologous versus HLA or genotypically matched related versus HLA mismatched transplants. Because at certain times in the HCT process risk is more unpredictable, HCT providers require different payment system strategies for the different time periods of care such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well as short- and long-term follow-up. Involvement by clinicians is essential for this process to be done well, especially given the rapid changes technological innovation brings to HCT. Constant dialogue and interaction between providers and payers on these difficult financial issues with HCT is essential to preserve patient access to this potentially lifesaving therapy.

KW - BMT

KW - Center for Medicare and Medicaid Services

KW - Compensation

KW - Managed care

UR - http://www.scopus.com/inward/record.url?scp=2942652697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942652697&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2004.03.004

DO - 10.1016/j.bbmt.2004.03.004

M3 - Article

VL - 10

SP - 427

EP - 432

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -